Insights Into Acute Myeloid Leukemia (AML) 2023
Perspectives of community physicians on the treatment of AML
Central – March 25, 2023
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Florida – October 14, 2023
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Northeast – October 14, 2023
Faculty Chair
Gail Roboz, MD
Medicine at Weill Cornell Medicine
Northwest – November 18, 2023
Faculty Chair
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX, USA
National – December 7, 2023
Faculty Co-Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Co-Chair
Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX, USA
More Information
- Houston, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of AML
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
